» Articles » PMID: 19920236

Cancer Incidence and Mortality After Treatment with Folic Acid and Vitamin B12

Overview
Journal JAMA
Specialty General Medicine
Date 2009 Nov 19
PMID 19920236
Citations 159
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Recently, concern has been raised about the safety of folic acid, particularly in relation to cancer risk.

Objective: To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials.

Design, Setting, And Participants: Combined analysis and extended follow-up of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo between 1998 and 2005, and were followed up through December 31, 2007.

Interventions: Oral treatment with folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) and vitamin B(6) (40 mg/d) (n = 1708); folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) (n = 1703); vitamin B(6) alone (40 mg/d) (n = 1705); or placebo (n = 1721).

Main Outcome Measures: Cancer incidence, cancer mortality, and all-cause mortality.

Results: During study treatment, median serum folate concentration increased more than 6-fold among participants given folic acid. After a median 39 months of treatment and an additional 38 months of posttrial observational follow-up, 341 participants (10.0%) who received folic acid plus vitamin B(12) vs 288 participants (8.4%) who did not receive such treatment were diagnosed with cancer (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03-1.41; P = .02). A total of 136 (4.0%) who received folic acid plus vitamin B(12) vs 100 (2.9%) who did not receive such treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; P = .01). A total of 548 patients (16.1%) who received folic acid plus vitamin B(12) vs 473 (13.8%) who did not receive such treatment died from any cause (HR, 1.18; 95% CI, 1.04-1.33; P = .01). Results were mainly driven by increased lung cancer incidence in participants who received folic acid plus vitamin B(12). Vitamin B(6) treatment was not associated with any significant effects.

Conclusion: Treatment with folic acid plus vitamin B(12) was associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway, where there is no folic acid fortification of foods.

Trial Registration: clinicaltrials.gov Identifier: NCT00671346.

Citing Articles

Recent Advances on the Role of B Vitamins in Cancer Prevention and Progression.

Frost Z, Bakhit S, Amaefuna C, Powers R, Ramana K Int J Mol Sci. 2025; 26(5).

PMID: 40076592 PMC: 11900642. DOI: 10.3390/ijms26051967.


Biological, dietetic and pharmacological properties of vitamin B.

Siatka T, Matus M, Moravcova M, Harcarova P, Lomozova Z, Matousova K NPJ Sci Food. 2025; 9(1):30.

PMID: 40075081 PMC: 11904035. DOI: 10.1038/s41538-025-00396-w.


Genetically predicted vitamins supplementation and risk of skin cancers: a Mendelian randomization study.

Qi P, Chen L, Ma A, Zhang Y, Lin H, Shi W Discov Oncol. 2025; 16(1):204.

PMID: 39969704 PMC: 11839550. DOI: 10.1007/s12672-025-01905-9.


Cardiovascular disease attenuates the protective effect of folate on global cognitive function in an elderly population: a cross-sectional study.

Zhang J, Yue D, Zhang H Sci Rep. 2025; 15(1):3327.

PMID: 39865092 PMC: 11770194. DOI: 10.1038/s41598-025-87129-x.


Folate metabolism in myelofibrosis: a missing key?.

Cerreto G, Pozzi G, Cortellazzi S, Pasini L, Di Martino O, Mirandola P Ann Hematol. 2025; 104(1):35-46.

PMID: 39847116 PMC: 11868374. DOI: 10.1007/s00277-024-06176-y.